The FDA Wants To Provide Clinical Research Guidelines for Cannabis


The Chemical Sciences Division at The National Institutes of Standards and Technology (NIST), an agency of the federal government “[whose] goal is to support U.S. industries by helping labs achieve high-quality measurements,” is implementing a new system that will more accurately measure the amounts of THC, CBD, pesticides, and other substances found in cannabis and its products. CannaQAP, is a Quality Assurance Program, will gather data on cannabis that will be reviewed by the FDA. Their mission with these findings is to discover the best way to establish consistency among laboratories; per Brent Wilson, research chemist at NIST, 

“When you walk into a store or dispensary and see a label that says 10% CBD, you want to know that you can trust that number.”

The American federal government’s involvement in this project has generated a buzz amongst protesters against the illegality of marijuana. The FDA‘s decision to incorporate cannabis into its repertoire of clinical research guidances may seem like a step in the right direction for some; to others, it still seems as though the public is waiting for something which may not even happen. It was last year that the DEA Acting Administrator Uttam Dhillon said in a press release by the National Media Affairs Office,

“[The] DEA is making progress in the program to register additional marijuana growers for federally authorized research, and will work with other relevant federal agencies to expedite the necessary next steps,” said DEA Acting Administrator Uttam Dhillon.  “We support additional research into marijuana and its components, and we believe registering more growers will result in researchers having access to a wider variety for study.”

A US congressional subcommittee panel was advised last week of the federal government’s sudden demand for cannabis research; thorough FDA analysis will not be able to be conducted until marijuana is either rescheduled or descheduled by the DEA, or, at long last, becomes federally legal, perhaps setting our embattled economy to flourish once again; 

“… it would be beneficial for state governments to legalize weed for both personal and commercial use. By cultivating small-business opportunities in every state, we would see a boom in the middle class we haven’t seen in decades,” said the former State Senator for New Hampshire, Brandon Phinney, in a recent statement. He continued: “Economically, legally, and socially, it’s the right thing to do.”